Fig. 4: Non-cancer cell infections enhance activation of antitumour CD8⁺ T cells.

a Representative flow cytometry plots of CTV dilution (top) and OT-I frequency among CD45⁺ cells (bottom) in TdLNs of M3-9-M^Res1- or M3-9-M^Res1/OVA-bearing mice after transfer of OT-I cells ± VSV^∆M51. b Count of OT-I cells in TdLNs of mice treated as in a (n = 7–10 mice/group, compiled from three independent experiments, one-way ANOVA with Tukey’s post-test). c Tumour growth (left) and overall survival (right) of M3-9-M^Res1-bearing mice treated with anti-PD-1 (n = 4 mice/group except n = 5 mice/group (d10 (125 µg), d10 (62.5 µg)), representative of 2 independent experiments, log-rank Mantel-Cox test on overall survival). d OT-I cell count in TdLNs of M3-9-M^Res1/OVA-bearing mice, post OT-I transfer and VSV^∆M51 and/or anti-PD-1 treatment (62.5 µg on day 10) (n = 10–18 mice/group, compiled from 3 independent experiments, one-way ANOVA with Tukey’s post-test). e Tumour growth (left) and overall survival (right) of M3-9-M^Res1-bearing mice treated as in d (left: n = 5 mice/group (control, αPD-1 (62.5 µg)), n = 7 mice/group (VSV, VSV + αPD-1 (62.5 µg)); right: n = 10–14 mice/group, compiled from 2 independent experiments, log-rank Mantel-Cox test). In all experiment, VSV^∆M51 was delivered i.v. at 5 × 10⁸ PFU. Points/bars at mean ± SD. Occasionally n is given as a range as the number of mice in each group varies. Please see the Source Data file for the exact n in each group.